What one analyst called “the single most important” nucleoside reverse transcriptase inhibitor in development – Merck & Co. Inc.’s islatravir – has met rocky terrain, with the firm and its partner, Gilead Sciences Inc., pausing combo trials.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aptevo, Dnatrix, Galapagos, Ocuphire, Oncotelic, Oramed, Santhera, Scynexis, Transgene.

Top-line results of Daiichi Sankyo Co. Ltd.’s phase III Quantum-First study, testing the addition of quizartinib to chemotherapy vs. chemotherapy alone for adults with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML), found the combination therapy provided a “statistically significant and clinically meaningful improvement” in overall survival vs. standard treatment alone, meeting the trial’s primary endpoint, Ken Takeshita, global head of R&D at Daiichi Sankyo, told BioWorld.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Achieve, Affimed, Akston, Amring, Amzell, Apollomics, Arctic Vision, Beigene, Catapult, Concentric, Daiichi, Day One, Diffusion, Exelixis, Imara, Innovent, Intellia, Lixte, Neoimmunetech, Noxxon, Pfizer, Pulmonem, Puma, Regeneron, Syneurx, Tennor, Zealand.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: 60 Degrees, Arena, Ascendis, Chimerix, Connect, Dermata, Enanta, Immunic, Immutep, Ionis, Jaguar, Kancera, Oncolys, Plus, Rain, Scancell, Todos, UCB, Vaxart.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: AL-S, Astrazeneca, Cassava Sciences, Daiichi Sankyo, Gannex, Imstem, Innovation, Kintara, Moderna, Ox2, Polypid, Tempest.